VC
PVLA

Voss Capital’s Palvella Therapeutics PVLA Stock Holding History

Voss Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-734
Closed -$122K – 56
2020
Q3 		$122K Sell
734
-825
-53% -$188K 0.07% 49
2020
Q2 		$387K Sell
1,559
-379
-20% -$88.6K 0.26% 36
2020
Q1 		$245K Buy
1,938
+63
+3% +$15.9K 0.33% 27
2019
Q4 		$543K Buy
+1,875
New +$520K 0.08% 91

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voss Capital's PVLA Position: Q4 2020 in Review

Voss Capital sold out of Palvella Therapeutics (PVLA) in Q4 2020, closing a stake of 734 shares — an estimated $122K sold.

Voss Capital first reported a position in PVLA in Q4 2019 and held it in 4 quarters. The position peaked at $543K in Q4 2019. 82 funds tracked by Wall St. Rank hold PVLA as of Q4 2020.

  • Voss Capital reported no remaining Palvella Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Voss Capital sold 734 Palvella Therapeutics shares in Q4 2020, an estimated $122K.
  • Voss Capital first reported a position in Palvella Therapeutics in Q4 2019 and held it in 4 quarters.
  • Voss Capital's Palvella Therapeutics position peaked at $543K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2020.

Based on Voss Capital's 13F filing for Q4 2020, filed 12 Feb 2021.